BioStem Announces Notice of Allowance for Three New U.S. Patent Applications
Expanding patent portfolio reinforces the Company’s commitment to wound care innovation, with 55 issued patents and 52 pending applications
POMPANO BEACH, Fla., May 28, 2025 (GLOBE NEWSWIRE) —
BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two design patents and one utility patent covering the Company’s novel fenestrated human placental allograft designs and compositions manufactured using the BioREtain® process.
The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for BioStem’s Design Patent Application No. 29/860,417 for FENESTRATED HUMAN PLACENTAL ALLOGRAFT and for Design Patent Application No. 29/860,420 for FENESTRATED HUMAN PLACENTAL ALLOGRAFT. These patents pertain to novel and inventive fenestrated human placental allograft designs manufactured using the BioREtain process. The unique design allows wound exudate to pass through the graft and away from the wound without sacrificing allograft area, thereby facilitating drainage and providing an environment that is more conducive to healing.
Additionally, the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for BioStem’s Patent Application No. 18/926,867 forSTERILE HUMAN PLACENTAL ALLOGRAFTS HAVING A PLURALITY OF SLITS, OPENINGS, AND/OR FENESTRATIONS FORMED THEREON. This patent pertains to novel and inventive fenestrated human placental allograft compositions manufactured using the BioREtain process with a unique fenestration that allows wound exudate to pass through the graft and away from the wound without sacrificing allograft area. The method of preparation preserves the structural and molecular integrity of the amnion and chorion tissues, thereby facilitating and enhancing wound treatment compared to conventional human placental allografts, particularly in the treatment of diabetic foot ulcers, dental wounds, and other topical wounds.